-
公开(公告)号:ZA9704688B
公开(公告)日:1997-12-30
申请号:ZA9704688
申请日:1997-05-28
Applicant: ABBOTT LAB
Inventor: BROOKS CLINT D W , KOLASA TEODOZYJ , LEE WENDY , STEWART ANDREW O
IPC: C07C317/32 , C07D209/14 , C07D257/04 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12 , C07D417/14 , C07D , A61K
CPC classification number: C07D257/04 , C07C317/32 , C07C2602/08 , C07D209/14 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12 , C07D417/14
-
公开(公告)号:AU3002395A
公开(公告)日:1996-02-16
申请号:AU3002395
申请日:1995-06-28
Applicant: ABBOTT LAB
Inventor: BROOKS DEE W , BHATIA PRAMILA , KOLASA TEODOZYJ , STEWART ANDREW O
IPC: A61K31/426 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/4409 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/498 , A61K31/505 , A61P11/00 , A61P11/06 , A61P17/06 , A61P19/02 , A61P19/06 , A61P27/14 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/22 , C07D215/227 , C07D215/36 , C07D235/12 , C07D239/26 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D513/04 , C07D215/26
Abstract: The present invention relates to a compound of formula W-X-Q-Y-CH(R1)-O-N=C(R2)-A-COM or a pharmaceutically acceptable salt thereof wherein W is optionally substituted aryl or heteroaryl; X is a valence bond, or methylene, divalent alkylene, alkenylene, alkynylene or alkyloxy; Q is a valence bond, or -O-, -S-, >NR4 or >NCOR5; Y is optionally substituted phenyl, biphenyl, naphthyl, tetrahydronaphthyl, indolyl, pyridyl, or benzo[b]thienyl, thienyl, thiazolyl, or thiazolylphenyl; R1 is alkyl, cycloalkyl, alkoxyalkyl, aryl or arylalkyl, heteroaryl or heteroarylalkyl; R2 is hydrogen, alkyl or hydroxyalkyl; A is a valence bond or is selected from alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, pyridylene, thienylene and furylene; and M is a pharmaceutically acceptable, metabolically cleavable group, -OR6, -NR6R7, -NH-tetrazoyl, -NH-2-, 3-, or 4-pyridyl, and -NH-2-, 4-, or 5-thiazolyl which inhibit leukotriene biosynthesis and are useful in the treatment of inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method for inhibiting lipoxygenase activity and leukotriene biosynthesis.
-
公开(公告)号:CA2191975A1
公开(公告)日:1996-02-01
申请号:CA2191975
申请日:1995-06-28
Applicant: ABBOTT LAB
Inventor: BROOKS DEE W , BHATIA PRAMILA , KOLASA TEODOZYJ , STEWART ANDREW O
IPC: A61K31/426 , A61K31/428 , A61K31/437 , A61K31/4406 , A61K31/4409 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/498 , A61K31/505 , A61P11/00 , A61P11/06 , A61P17/06 , A61P19/02 , A61P19/06 , A61P27/14 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/22 , C07D215/227 , C07D215/36 , C07D235/12 , C07D239/26 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D513/04 , C07D417/02 , C07D209/04 , C07D235/04 , C07D215/16 , A61K31/195 , C07D277/22 , A61K31/395 , C07D241/40 , C07C251/50 , C07D213/55
Abstract: The present invention relates to a compound of the formula: W-X-Q-Y-CH(R1)-O-N=C(R2)-A-COM, or a pharmaceutically acceptable salt thereof wherein W is optionally substituted aryl or heteroaryl; X is a valence bond, or methylene, divalent alkylene, alkenylene, alkynylene or alkyloxy; Q is a valence bond, or -O-, -S-, > NR4 or > NCOR5; Y is optionally substituted phenyl, biphenyl, naphthyl, tetrahydronaphthyl, indolyl, pyridyl, or benzo¢b!thienyl, thienyl, thiazolyl, or thiazolylphenyl; R1 is alkyl, cycloalkyl, alkoxyalkyl, aryl or arylalkyl, heteroaryl or heteroarylalkyl; R2 is hydrogen, alkyl or hydroxyalkyl; A is a valence bond or is selected from alkylene, alkenylene, alkynylene, cycloalkylene, phenylene, pyridylene, thienylene and furylene; and M is a pharmaceutically acceptable, metabolically cleavable group, -OR6, NR6R7, -NH-tetrazoyl, -NH-2-, 3-, or 4-pyridyl, and -NH-2-, 4-, or 5-thiazolyl which inhibit leukotriene biosynthesis and are useful in the treatment of inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method for inhibiting lipoxygenase activity and leukotriene biosynthesis.
-
公开(公告)号:PE08042011A1
公开(公告)日:2011-11-30
申请号:PE0006262011
申请日:2009-09-16
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , LATSHAW STEVEN P , KOLASA TEODOZYJ , LI TONGMEI , PEDDI SRIDHAR , LIU BO , PEREZ-MEDRANO ARTURO , PATEL MEENA , WANG XUEQING , NELSON DEREK W
IPC: C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
CPC classification number: C07D405/12 , C07D231/40 , C07D285/135 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE X4 ES O, S, S(O), N(Rbx); Rbx ES H, ALQUILO, -C(O)O(ALQUILO); A1 ES -(CR1aR1b)q1-A2, -(CR1aR1b)q1-G1c, ENTRE OTROS; R1a Y R1b SON CADA UNO H, HALOGENO, ALQUILO C1-C4, ALQUILO C1-C4, ENTRE OTROS q1 ES 1-4; G1c ES CICLOALQUENILO, HETEROCICLO, ARILO, HETEROARILO; A2 ES -CO, -SO2, ENTRE OTROS; A5 ES DE PREFERENCIA PIRAZOL, 1,3,4-TIADIAZOL, ENTRE OTROS; RX ES C1-C4 ALQUILO, HALOGENO, NO2, ENTRE OTROS; z ES 0-4. SON COMPUESTOS PREFERIDOS: N-{(3E)-5-TERT-BUTIL-1-METIL-2-[(2R)-TETRAHIDROFURAN-2-ILMETIL]-1,2-DIHIDRO-3H-PIRAZOL-3-ILIDEN}-2-[(2R)-TETRAHIDROFURAN-2-ILMETOXI]-5-(TRIFLUOROMETIL)BENZAMIDA; N-[(2Z)-3-BUTIL-5-TERT-BUTIL-1,3,4-TIADIAZOL-2(3H)-ILIDEN]-2-(2-HIDROXI-2-METILPROPOXI)-5-(TRIFLUOROMETIL)BENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE PRESENTA UN BIODISPONIBILIDAD ORAL MAYOR O IGUAL A 30%. DICHOS COMPUESTOS SON LIGANDOS DE RECEPTORES DE CANNABINOIDES UTIL EN EL TRATAMIENTO DEL DOLOR
-
公开(公告)号:CR20110170A
公开(公告)日:2011-06-22
申请号:CR20110170
申请日:2011-03-28
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , LATSHAW STEVEN P , KOLASA TEODOZYJ , LI TONGMEI , PEDDI SRIDHAR , LIU BO , PEREZ-MEDRANO ARTURO , PATEL MEENA , WANG XUEQING , NELSON DEREK W
IPC: C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
Abstract: Ligandos de receptores de canabinoides de la fórmula (I), en donde A1, A5, Rx, X4 y z son como se definen en la memoria descriptiva. Se divulgan asimismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones.
-
公开(公告)号:CL2011000544A1
公开(公告)日:2011-06-17
申请号:CL2011000544
申请日:2011-03-15
Applicant: ABBOTT LAB
Inventor: LIU , CARROL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , LASTSHAW STEVEN P , KOLASA TEODOZYJ , LI TONGMEY , PEDDI SRIDHAR
IPC: A61K31/4155 , A61P29/00 , C07D231/40
Abstract: Compuestos derivados de benzamida sustituida; composición farmacéutica; y su uso para tratar el dolor, entre otras enfermedades.
-
公开(公告)号:ECSP11010974A
公开(公告)日:2011-05-31
申请号:ECSP11010974
申请日:2011-04-12
Applicant: ABBOTT LAB
Inventor: KOLASA TEODOZYJ , DART MICHAEL J , CARROLL WILLIAM A , FROST JENNIFER M , LI TONGMEL , NELSON DEREK W , PATEL MEENA V , PEDDI SRIDHAR , PEREZ-MEDRANO ARTURO , LATSHAW STEVEN P , LIU BO , WANG XUEQING
IPC: C07D231/40 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14
Abstract: Ligandos de receptores de canabinoides de la fórmula (I) (consta diseño) en donde A1, A5, Rx, X4 y z son como se definen en la memoria descriptiva. Se divulgan asimismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones.
-
公开(公告)号:MX2011001755A
公开(公告)日:2011-03-24
申请号:MX2011001755
申请日:2009-08-11
Applicant: ABBOTT LAB
Inventor: DART MICHAEL J , CARROLL WILLIAM A , LIU BO , KOLASA TEODOZYJ , FROST JENNIFER M , LATSHAW STEVEN P , PEREZ-MEDRANO ARTURO , PATEL MEENA V , WANG XUEQUING
IPC: C07D261/14 , A61K31/433 , A61P29/00 , C07D285/135 , C07D407/06 , C07D417/06
Abstract: Se describen ligandos de receptor canabinoide de la fórmula (I), en donde Y, X1, X2, X3, R1 y R2 son tal como se define en la especificación: También se describen composiciones que comprenden dichos compuestos, y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones.
-
公开(公告)号:CA2737199A1
公开(公告)日:2010-03-25
申请号:CA2737199
申请日:2009-09-16
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , LATSHAW STEVEN P , KOLASA TEODOZYJ , LI TONGMEI , PEDDI SRIDHAR , LIU BO , PEREZ-MEDRANO ARTURO , PATEL MEENA , WANG XUEQING , NELSON DEREK W
IPC: C07D231/40 , A61K31/4155 , A61K31/433 , A61P29/00 , C07D285/135 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: Disclosed herein are cannabinoid receptor ligands of formula (I), wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
-
公开(公告)号:CA2734527A1
公开(公告)日:2010-03-11
申请号:CA2734527
申请日:2009-09-08
Applicant: ABBOTT LAB
Inventor: CARROLL WILLIAM A , DART MICHAEL J , FROST JENNIFER M , KOLASA TEODOZYJ , LI TONGMEI , LIU BO , PEREZ-MEDRANO ARTURO , PATEL MEENA , WANG XUEQING , PEDDI SRIDHAR
IPC: C07D277/46 , A61K31/427 , A61P29/00 , C07D417/06 , C07D417/14
Abstract: The present application relates to cannabinoid receptor ligands of formula (I), wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
-
-
-
-
-
-
-
-
-